Document 0093
 DOCN  M94A0093
 TI    Lipid-based amphotericin B in the treatment of cryptococcosis.
 DT    9412
 AU    Viviani MA; Rizzardini G; Tortorano AM; Fasan M; Capetti A; Roverselli
       AM; Gringeri A; Suter F; Laboratorio di Micologia Medica, Universita
       degli Studi di; Milano, Italy.
 SO    Infection. 1994 Mar-Apr;22(2):137-42. Unique Identifier : AIDSLINE
       MED/94350503
 AB    Amphotericin B is the only antifungal drug which, despite its
       dose-limiting toxicity, can be given intravenously when an aggressive
       treatment is required. In an attempt to reduce the drug toxicity while
       retaining its therapeutic efficacy, new formulations of amphotericin B
       have been developed. The most promising have employed lipid vehicles
       such as liposomes. Three lipid-based amphotericin B formulations have
       been developed by pharmaceutical companies and are under active clinical
       investigation. Efficacy and safety data of these derivatives in animals
       and humans are reviewed, with particular concern to cryptococcal
       infection. The authors' experience with a small unilamellar liposomal
       amphotericin B formulation, AmBisome, in the primary therapy of
       cryptococcosis is reported. Nine AIDS patients affected with
       cryptococcosis, seven of whom had meningitis, were given AmBisome (3
       mg/kg/day) for 3-6 weeks. Complete response was obtained in six
       patients, marked improvement in two, and failure in one. AmBisome was
       well tolerated and shortened the time to clinical and mycological
       response suggesting a further improvement in the management of
       cryptococcosis in AIDS patients.
 DE    Adult  Amphotericin B/*ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC
       USE  AIDS-Related Opportunistic Infections/BLOOD/DIAGNOSIS/*DRUG
       THERAPY  Chemistry, Pharmaceutical  Cryptococcosis/BLOOD/DIAGNOSIS/*DRUG
       THERAPY  Drug Carriers  Drug Evaluation  Human  Leukocyte Count
       Liposomes  Male  Middle Age  Pilot Projects  Time Factors  Treatment
       Outcome  T4 Lymphocytes  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).